JAC Advance Access first published online on July 22, 2005
This version published online on July 27, 2005
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dki248
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Infectious Diseases Research, Ochsner Clinic Foundation LT 7S, 1514 Jefferson Highway, New Orleans, LA 70121-2483, USA
* To whom correspondence should be addressed. New antimicrobial agents are urgently needed for clinical use due to the increasing prevalence and spread of multidrug-resistant bacteria that are commonly responsible for serious and life-threatening diseases. The need to develop new agents that effectively overcome existing mechanisms of resistance displayed by bacteria resistant to currently available drugs has become paramount. Tigecycline, the first in a new class of antimicrobials, the glycylcyclines, is an analogue of minocycline with additional properties that negate most mechanisms mediating resistance to the tetracyclines. In vitro testing has revealed that tigecycline has activity against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus, penicillin-resistant Streptococcus pneumoniae and many species of multidrug-resistant Gram-negative bacteria, although resistance to tigecycline by Pseudomonas aeruginosa and reduced susceptibility among Proteus species do occur. Tigecycline is being evaluated in multicentre Phase III clinical trials for therapy of many serious and life-threatening infections in which multidrug-resistant bacterial organisms may be found. Tigecycline appears to hold promise as a novel expanded spectrum antibiotic.
Review
Tigecycline
George A. Pankey, E-mail: gpankey{at}ochsner.org
Abstract
The originally published version of this article was incorrect. The last sentence of the Note added in proof referred to breakpoints for aerobes instead of anaerobes. The publisher apologizes for this error.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  D. Curcio Off-label use of antibiotics in hospitalized patients: focus on tigecycline J. Antimicrob. Chemother., December 1, 2009; 64(6): 1344 - 1346. [Full Text] [PDF]
|
|
|
|
|
|
T. Kelesidis, D. E. Karageorgopoulos, I. Kelesidis, and M. E. Falagas Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae: a systematic review of the evidence from microbiological and clinical studies J. Antimicrob. Chemother., November 1, 2008; 62(5): 895 - 904. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Fernandez-Roblas, N. Z. Martin-de-Hijas, A. I. Fernandez-Martinez, D. Garcia-Almeida, I. Gadea, and J. Esteban In Vitro Activities of Tigecycline and 10 Other Antimicrobials against Nonpigmented Rapidly Growing Mycobacteria Antimicrob. Agents Chemother., November 1, 2008; 52(11): 4184 - 4186. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Starr, G. W. Fox, and J. K. Clayton Streptococcus pneumoniae: An Update on Resistance Patterns in the United States Journal of Pharmacy Practice, October 1, 2008; 21(5): 363 - 370. [Abstract] [PDF]
|
|
|
|
|
|
A. P. MacGowan Tigecycline pharmacokinetic/pharmacodynamic update J. Antimicrob. Chemother., September 1, 2008; 62(suppl_1): i11 - i16. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. E. Karageorgopoulos, T. Kelesidis, I. Kelesidis, and M. E. Falagas Tigecycline for the treatment of multidrug-resistant (including carbapenem-resistant) Acinetobacter infections: a review of the scientific evidence J. Antimicrob. Chemother., July 1, 2008; 62(1): 45 - 55. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Curcio Treatment of Recurrent Urosepsis with Tigecycline: a Pharmacological Perspective J. Clin. Microbiol., May 1, 2008; 46(5): 1892 - 1893. [Full Text] [PDF]
|
|
|
|
|
|
J. Vouillamoz, P. Moreillon, M. Giddey, and J. M. Entenza In vitro activities of tigecycline combined with other antimicrobials against multiresistant Gram-positive and Gram-negative pathogens J. Antimicrob. Chemother., February 1, 2008; 61(2): 371 - 374. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. P. Zavascki, L. Z. Goldani, J. Li, and R. L. Nation Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review J. Antimicrob. Chemother., December 1, 2007; 60(6): 1206 - 1215. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Deplano, O. Denis, C. Nonhoff, F. Rost, B. Byl, F. Jacobs, V. Vankerckhoven, H. Goossens, and M. J. Struelens Outbreak of hospital-adapted clonal complex-17 vancomycin-resistant Enterococcus faecium strain in a haematology unit: role of rapid typing for early control J. Antimicrob. Chemother., October 1, 2007; 60(4): 849 - 854. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Y. Song, S. Y. Kee, I. S. Hwang, Y. B. Seo, H. W. Jeong, W. J. Kim, and H. J. Cheong In vitro activities of carbapenem/sulbactam combination, colistin, colistin/rifampicin combination and tigecycline against carbapenem-resistant Acinetobacter baumannii J. Antimicrob. Chemother., August 1, 2007; 60(2): 317 - 322. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Curcio and F. Fernandez Acinetobacter spp. susceptibility to tigecycline: a worldwide perspective J. Antimicrob. Chemother., August 1, 2007; 60(2): 449 - 450. [Full Text] [PDF]
|
|
|
|
|
|
D. Curcio, F. Fernandez, R. N. Jones, M. J. Ferraro, L. B. Reller, P. C. Schreckenberger, and H. S. Sader Tigecycline Disk Diffusion Breakpoints of Acinetobacter spp.: a Clinical Point of View J. Clin. Microbiol., June 1, 2007; 45(6): 2095 - 2096. [Full Text] [PDF]
|
|
|
|
|
|
K. A. Rodvold, M. H. Gotfried, M. Cwik, J. M. Korth-Bradley, G. Dukart, and E. J. Ellis-Grosse Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose J. Antimicrob. Chemother., December 1, 2006; 58(6): 1221 - 1229. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. E. Nord, E. Sillerstrom, and E. Wahlund Effect of tigecycline on normal oropharyngeal and intestinal microflora. Antimicrob. Agents Chemother., October 1, 2006; 50(10): 3375 - 3380. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Denis, A. Deplano, C. Nonhoff, M. Hallin, R. De Ryck, R. Vanhoof, R. De Mendonca, and M. J. Struelens In Vitro Activities of Ceftobiprole, Tigecycline, Daptomycin, and 19 Other Antimicrobials against Methicillin-Resistant Staphylococcus aureus Strains from a National Survey of Belgian Hospitals. Antimicrob. Agents Chemother., August 1, 2006; 50(8): 2680 - 2685. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Kasbekar Tigecycline: A new glycylcycline antimicrobial agent. Am. J. Health Syst. Pharm., July 1, 2006; 63(13): 1235 - 1243. [Abstract] [Full Text] [PDF]
|
|